Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera

Clinical and Vaccine Immunology : CVI
Isabelle HenckaertsJan Poolman

Abstract

A comparative study was conducted between two laboratories in order to evaluate the differences between two enzyme-linked immunosorbent assay (ELISA) techniques for the detection of pneumococcal anti-capsular polysaccharide antibodies. One laboratory used an assay including heterologous 22F polysaccharide inhibition, and the other laboratory employed a non-22F reference assay. After conjugate immunization, 30 pediatric post-primary immunization sera with antipolysaccharide concentrations ranging from <0.05 to 15 mug/ml were analyzed. Aggregate reverse cumulative distribution curves combining concentrations of antibodies against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F revealed similar results for both methods at antibody levels of >1 microg/ml. However, at antibody levels of <1 microg/ml, the distribution curve measured with the 22F inhibition ELISA shifted toward lower levels. This observation suggests that the 22F inhibition assay is more specific at low antibody concentrations, which was confirmed by heterologous polysaccharide inhibition experiments. Translation of low antibody levels suggested that the proposed threshold concentration of 0.35 mug/ml determined with the non-22F ELISA corresponded to a concentration of 0.2...Continue Reading

References

Sep 1, 1995·Clinical and Diagnostic Laboratory Immunology·S A QuataertD V Madore
May 9, 2000·Clinical and Diagnostic Laboratory Immunology·A SoininenH Käyhty
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group

❮ Previous
Next ❯

Citations

Dec 18, 2013·The Pediatric Infectious Disease Journal·Maria Deloria KnollKatherine L O'Brien
Sep 5, 2006·Journal of Clinical Pathology·Paul BalmerRay Borrow
Dec 18, 2013·Journal of Clinical Immunology·Ricardo U Sorensen, Lily E Leiva
Nov 4, 2009·Expert Review of Anti-infective Therapy·Ener Cagri Dinleyici, Zeynel Abidin Yargic
Dec 22, 2006·Expert Review of Vaccines·Helena KäyhtyHelena Mäkelä
Oct 30, 2009·Expert Review of Vaccines·Roman Prymula, Lode Schuerman
Sep 21, 2012·Expert Opinion on Biological Therapy·David Pace
Sep 16, 2011·Vaccine·Adriano ArguedasArturo Abdelnour
Feb 26, 2010·Biosensors & Bioelectronics·Johannes BaaderIngo Freund
Oct 12, 2015·Immunology and Allergy Clinics of North America·Luke A WallRicardo U Sorensen
Nov 17, 2012·Vaccine·Tomohiro OishiUNKNOWN Japanese IPD Study Group
May 10, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Joon Young SongMoon H Nahm
Oct 14, 2014·Frontiers in Immunology·Rohan AmeratungaSee-Tarn Woon
Oct 1, 2016·Expert Review of Vaccines·Qi LiangFeng-Cai Zhu
Sep 4, 2009·Paediatric Drugs·Jamie D Croxtall, Gillian M Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.